RxDoctor Payments Data

James Gulde, MD

Internal Medicine · Sulphur Springs, TXNPI 1881682987

Payments from drug & device makers

$326in general payments, 2019–2025

Across 9 payments — averaging $36.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$177
  • Medtronic$68
  • AbbVie$37
  • AstraZeneca$18
  • Amgen$14
  • Novo Nordisk$11

What the payments were for

  • Food & beverage$326100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK2$177
Medtronic1$68
AbbVie(2 entities)3$37
AstraZeneca1$18
Amgen1$14
Novo Nordisk1$11

How this compares

$326 in reported general payments places this provider in the 50th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$119,150
Medicare patients
500
Services billed
1,724

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban758$305,588
OzempicSemaglutide159$157,040
MounjaroTirzepatide94$104,414
JardianceEmpagliflozin162$78,705
FarxigaDapagliflozin Propanediol128$74,558
RybelsusSemaglutide42$55,380
OtezlaApremilast25$55,281
XareltoRivaroxaban141$49,631
EnbrelEtanercept13$49,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$48,257
EntrestoSacubitril/Valsartan81$45,738
LinzessLinaclotide63$44,792
XifaxanRifaximin29$43,800
TrulicityDulaglutide28$42,905
JanuviaSitagliptin Phosphate133$41,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$11$212,420201 claims
AstraZenecaFarxiga, Symbicort, Brilinta$18$111,060231 claims
AmgenOtezla, Enbrel$14$104,30138 claims
AbbVieLinzess, Creon$37$72,89289 claims
GSKTrelegy Ellipta$177$48,25772 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sulphur Springs

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →